<DOC>
	<DOCNO>NCT02057978</DOCNO>
	<brief_summary>The purpose Randomized Study evaluate safety efficacy Excel-II DES compare EXCEL DES treatment patient de novo coronary artery lesion .</brief_summary>
	<brief_title>EXCEL-II Stent Vesus EXCEL Stent Treat Patients With de Novo Coronary Artery Lesions .</brief_title>
	<detailed_description>The primary end point observe in-stent late lumenn loss 9 month stent implantation . This study base non-inferior assumption ( vs. EXCEL-II V EXCEL Stent ) , requring end point reach statictic significance . Quality assurance plan address data validation registry procedure , include plan site monitoring audit . Data check compare data enter registry predefined rule range consistency data field registry . Source data verification ass accuracy , completeness , representativeness registry data compare data external data source ( e.g. , medical record , paper electronic case report form , interactive voice response system ) . Data dictionary contains detailed description variable used registry , include source variable , cod information use normal range relevant . Standard Operating Procedures address registry operation analysis activity , patient recruitment , data collection , data management , data analysis , report adverse event , change management . Sample size assessment specify number participant participant year necessary demonstrate effect . Plan miss data address situation variable report miss , unavailable , `` non-reported , '' uninterpretable , consider miss data inconsistency out-of-range result Statistical analysis plan describe analytical principle statistical technique employ order address primary secondary objective , specify study protocol plan .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<criteria>Inclusion criterion : 1.18yrs≤Age≤75yrs . 2.stability unstable angina pectoris ( AP ) , chronic myocardial infarction ( OMI ) confirm myocardial ischemia ; 3.De novo lesion native coronary artery ( Up two target lesion ) . 4.Lesion length ≤32mm . 5.RVD 2.5mm～4.0mm . 6.DS % ≥70 % visual test . 7.Coronary artery bypass surgery ( coronary artery bypass graft ) patient . 8.Subjects willing follow specify requirement followup . 9.To understand purpose trial willing sign inform consent accept clinical followup . 1 . AMI within 7 day . 2 . CTO ( TIMI 0 ) , leave main lesion , ostial lesion transplant vascular lesion , bifurcation lesion ( reference collateral blood vessel diameter 2.5 mm high ) , stent restenosis lesion deal three pathological change ; 3 . Severe calcified lesion unable predilate . 4 . The distortion stent hamper lesion . 5 . NYHA≥Ⅲ LVEF＜40 % . 6 . Prior PCI within 1 year . 7 . Pregnancy lactation , plan pregnancy lactation . 8 . Subjects bleed tendency blood coagulation dysfunction PCI contraindication , anticoagulant therapy taboo ca n't continue take DAPT least 1 year . 9 . There diseases ( cancer , malignant tumor , congestive heart failure , organ transplantation candidate ) abuse history ( alcohol cocaine heroin , etc . ) , scheme compliance poor , interference relate data explanation limited life ( &lt; 1 year ) . 10 . To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent one allergy . 11 . Serious liver kidney function complete subject ( ALT AST three time great upper limit normal ) . 12 . Before enrol participate clinical trial reach primary endpoint . 13 . Noncompliant subject could finish trial accordance requirement subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Late Lumen Loss</keyword>
	<keyword>MACE</keyword>
	<keyword>Death</keyword>
	<keyword>TLF</keyword>
	<keyword>Thrombosis ( definite probable )</keyword>
</DOC>